title: Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity.
abstract: The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated killing of hematopoietic stem cells. Specific clinical applications must therefore be conceived to bypass these limitations.
authors.affiliation: Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany ; Clinical Cooperation Group "Immune Monitoring"; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany.
authors.forename: Dolores J
authors.initials: DJ
authors.lastname: Schendel
authors.forename: Bernhard
authors.initials: B
authors.lastname: Frankenberger
keywords: MHC-restricted fratricide; TCR gene therapy; hematopoietic stem cell toxicity; hyluronan-mediated motility receptor; survivin